Drugs / Recombinant novel coronavirus vaccine (CHO cells)
Recombinant novel coronavirus vaccine (CHO cells)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05198063 | Jan → Aug 2022 | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05198102 | Dec 2021 → Jul 2022 | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05895110 | Apr → Nov 2022 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant novel coronavirus vaccine (CHO cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198102 ↗ |
| Modality | Vaccine | “recombinant novel coronavirus vaccine (CHO cells)” NCT05198063 ↗ |
| Route | Intramuscular | “Intramuscular injection of deltoid muscle of upper arm” NCT05198063 ↗ |